Pharmaceutical companies rely on Syed's research and analysis to help them bring generic drugs quickly to consumers.
Syed provides critical research and analysis to steer clients around intellectual property roadblocks in the development of new and generic drugs. He assists our clients and attorneys in all phases of patent litigation and patent prosecution, primarily focusing on companies filing Abbreviated New Drug Applications (ANDA). Using his research experience in biochemistry, organic and inorganic syntheses, and analytical chemistry, he creates winning strategies for Paragraph IV certifications. He also develops technical analyses to support patent challenges in the filing of inter partes reviews (IPR).
Syed has been involved in analyzing patents and conducting technical research on over 70 pharmaceutical products, and his experience is invaluable in ANDA cases. These include Boniva® (ibandronate sodium), Actonel® (risedronate sodium), Megace® ES (megestrol acetate), Treanda® (bendamustine), Dexilant (dexlansoprazole), Oxtellar XR® (oxcarbazepine), Lidoderm® (lidocaine), Letairis® (ambrisentan), Adderall XR® (mixed amphetamine salts), Eliquis® (apixaban), Riomet® (Metformin), Isosulfan Blue, Trintellix® (vortioxetine hydrobromide), Entresto® (sacubitril-valsartan), Gilenya® (fingolimod) and Sprycel® (dasatinib). His research often leads to a victory or settlement, resulting in getting generic drugs to market faster and saving litigation costs for clients.
If a patent challenge results in litigation, Syed assists in discovery, works with expert witnesses in testimony preparation and attends court proceedings, conferring with our litigation attorneys to offer further insight and inform their questioning and arguments.
Syed also researches and advises on patent litigation and prosecution cases involving polymers, medical devices, radioisotopes, and animal drugs.